Abstract
Methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydofolate (CH2-H4folate) to 5- methyltetrahydrofolate (CH3-H4folate). The enzyme employs a noncovalently-bound flavin adenine dinucleotide (FAD), which accepts reducing equivalents from NAD(P)H and transfers them to CH2-H4folate. The reaction provides the sole source of CH3-H4folate, which is utilized by methionine synthase in the synthesis of methionine from homocysteine. MTHFR plays a key role in folate metabolism and in the homeostasis of homocysteine; mutations in the enzyme lead to hyperhomocyst(e)inemia. A common C677T polymorphism in MTHFR has been associated with an increased risk for the development of cardiovascular disease, Alzheimer’s disease, and depression in adults, and of neural tube defects in the fetus. The mutation also confers protection for certain types of cancers. This review presents the current knowledge of the enzyme, its biochemical characterization, and medical significance.
Keywords: Flavin, FAD, folate, MTHFR, methylenetetrahydrofolate, methyltetrahydrofolate, homocysteine, C677T polymorphism
Current Pharmaceutical Design
Title:Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Volume: 19 Issue: 14
Author(s): Elizabeth E. Trimmer
Affiliation:
Keywords: Flavin, FAD, folate, MTHFR, methylenetetrahydrofolate, methyltetrahydrofolate, homocysteine, C677T polymorphism
Abstract: Methylenetetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5,10-methylenetetrahydofolate (CH2-H4folate) to 5- methyltetrahydrofolate (CH3-H4folate). The enzyme employs a noncovalently-bound flavin adenine dinucleotide (FAD), which accepts reducing equivalents from NAD(P)H and transfers them to CH2-H4folate. The reaction provides the sole source of CH3-H4folate, which is utilized by methionine synthase in the synthesis of methionine from homocysteine. MTHFR plays a key role in folate metabolism and in the homeostasis of homocysteine; mutations in the enzyme lead to hyperhomocyst(e)inemia. A common C677T polymorphism in MTHFR has been associated with an increased risk for the development of cardiovascular disease, Alzheimer’s disease, and depression in adults, and of neural tube defects in the fetus. The mutation also confers protection for certain types of cancers. This review presents the current knowledge of the enzyme, its biochemical characterization, and medical significance.
Export Options
About this article
Cite this article as:
E. Trimmer Elizabeth, Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance, Current Pharmaceutical Design 2013; 19(14) . https://dx.doi.org/10.2174/1381612811319140008
DOI https://dx.doi.org/10.2174/1381612811319140008 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Hypertensive Heart Disease and the Role of Aldosterone Antagonists
Current Hypertension Reviews Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The Effect of Polyphenol Consumption on Blood Pressure
Mini-Reviews in Medicinal Chemistry Optimization and Assay of Antioxidant Potential of Two Penicillium spp. by Different Procedures
Current Biotechnology Association of Low Vitamin D with Complications of HIV and AIDS: A literature Review
Infectious Disorders - Drug Targets Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology The Coronary Circulation in Cyanotic Congenital Heart Disease
Current Cardiology Reviews TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research Genetic Determinants of Vitamin D-Related Disorders; Focus on Vitamin D Receptor
Current Drug Metabolism An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Treatment of Foot Disease in Patients with Type 2 Diabetes Mellitus using Human Umbilical Cord Blood Mesenchymal Stem Cells: Response and Correction of Immunological Anomalies
Current Pharmaceutical Design Are Carbonic Anhydrase Inhibitors Suitable for Obtaining Antiobesity Drugs ?
Current Pharmaceutical Design MicroRNAs: Important Epigenetic Regulators in Osteoarthritis
Current Genomics Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends
Current Pharmaceutical Design Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine
CNS & Neurological Disorders - Drug Targets Hypertension in Obstructive Sleep Apnoea
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: Modifying Cardiovascular Risk Factors: Newer Advances in Cardiovascular Metabolism and Diagnostic Technologies)
Current Pharmaceutical Design